Updated:
Chiesi Farmaceutici
Chiesi Farmaceutici is a 90-year-old family-controlled biopharmaceutical group headquartered in Parma, Italy, led by president Maria Paola Chiesi.
Chiesi Farmaceutici
General information
Firm type
Single Family Office
Year founded
1926
AUM
Undisclosed
Location
Region
North America
Country
Italy
City
Parma
Corporate office
Parma, Italy
Additional offices
Columbus, OH, United States · Toronto, Canada
Principals
Maria Paola Chiesi
President of the Board of Directors
Alessandro Chiesi
Vice President
Jean-Marc Bellemin
CEO ad interim and CFO
Giacomo Chiesi
Executive Vice President, Chiesi Global Rare Diseases
Sector focus
Frequently asked questions
Who controls Chiesi Farmaceutici?
Chiesi Farmaceutici is wholly controlled by the Chiesi family. The board is led by President Maria Paola Chiesi, who took over in May 2026, with Vice President Alessandro Chiesi. Leadership transitions remain intergenerational.
What are Chiesi's primary therapeutic areas?
Chiesi operates in three core therapeutic areas: respiratory health (Air), rare diseases (Rare), and specialty care (Care). In 2025, the respiratory franchise generated €1.886 billion in revenue, rare diseases €906 million, and specialty care €904 million.
Has Chiesi made any major acquisitions recently?
In April 2026, Chiesi agreed to acquire KalVista Pharmaceuticals for approximately $1.9 billion in cash. The deal adds sebetalstat, an oral on-demand therapy for hereditary angioedema, to Chiesi's rare-disease portfolio.
Is Chiesi structured as a B Corp?
Yes. Chiesi has been a certified B Corp since 2019 and operates as a Benefit Corporation in Italy, the United States, France, and Colombia. This legal status mandates the company to balance profit with purpose across social and environmental dimensions.
How much does Chiesi invest in R&D?
In 2025, Chiesi invested a record €885 million in research and development, equivalent to 24.4% of consolidated revenue. R&D centers are located in Italy, France, the United States, Canada, China, the United Kingdom, and Sweden.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: